Compare SSTI & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTI | VOR |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 776.5M |
| IPO Year | 2017 | 2021 |
| Metric | SSTI | VOR |
|---|---|---|
| Price | $7.59 | $15.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $15.00 | ★ $45.33 |
| AVG Volume (30 Days) | 90.9K | ★ 800.4K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,753,000.00 | N/A |
| Revenue This Year | $7.43 | N/A |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.25 | N/A |
| 52 Week Low | $5.78 | $0.18 |
| 52 Week High | $16.92 | $49.95 |
| Indicator | SSTI | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 49.37 |
| Support Level | $6.16 | $13.73 |
| Resistance Level | $7.85 | $16.87 |
| Average True Range (ATR) | 0.41 | 0.98 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 90.61 | 25.67 |
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes: ShotSpotter, the acoustic gunshot detection system; CrimeTracer, the foremost law enforcement search engine; CaseBuilder, a one-stop investigation management system; ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact; PlateRangerTM powered by Rekor, an automatic license plate recognition ("ALPR") and vehicle identification solution; SafePointe, an AI-based weapons detection system.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.